UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Biomarkers for neurodegenerative diseases

Nature medicine, 2021-06, Vol.27 (6), p.954-963

Hansson, Oskar

2021

Link zum Volltext

Verfügbarkeit prüfen

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Nature medicine, 2020-03, Vol.26 (3), p.379-386

2020

Link zum Volltext

Verfügbarkeit prüfen

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Nature communications, 2021-06, Vol.12 (1), p.3555-3555, Article 3555

2021

Link zum Volltext

Verfügbarkeit prüfen

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

Alzheimer's research & therapy, 2019-04, Vol.11 (1), p.34-34, Article 34

2019

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Nature communications, 2020-04, Vol.11 (1), p.1683-1683, Article 1683

2020

Link zum Volltext

Verfügbarkeit prüfen

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Nature communications, 2020-12, Vol.11 (1), p.6252-6252, Article 6252

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Nature medicine, 2021-06, Vol.27 (6), p.1034-1042

2021

Link zum Volltext

Verfügbarkeit prüfen

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Lancet neurology, 2022-01, Vol.21 (1), p.66-77

2022

Link zum Volltext

Verfügbarkeit prüfen

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease

BMC neurology, 2020-01, Vol.20 (1), p.10-10, Article 10

2020

Link zum Volltext

Verfügbarkeit prüfen

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

Nature communications, 2017-10, Vol.8 (1), p.1214-13, Article 1214

2017

Link zum Volltext

Verfügbarkeit prüfen

Blood‐based biomarkers for Alzheimer's disease

EMBO molecular medicine, 2022-01, Vol.14 (1), p.e14408-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Relationship between cortical iron and tau aggregation in Alzheimer's disease

Brain (London, England : 1878), 2020-05, Vol.143 (5), p.1341-1349

2020

Link zum Volltext

Verfügbarkeit prüfen

CSF biomarkers and clinical progression of Parkinson disease

Neurology, 2015-01, Vol.84 (1), p.57

2015

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

Movement disorders, 2016-06, Vol.31 (6), p.898-905

2016

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948

European journal of nuclear medicine and molecular imaging, 2020-02, Vol.47 (2), p.342-354

2020

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease

Brain (London, England : 1878), 2020-12, Vol.143 (11), p.3234-3241

2020

Link zum Volltext

Verfügbarkeit prüfen

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

JAMA : the journal of the American Medical Association, 2020-08, Vol.324 (8), p.772

2020

Link zum Volltext

Verfügbarkeit prüfen

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

JAMA neurology, 2017-12, Vol.74 (12), p.1492

2017

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

Nature communications, 2020-01, Vol.11 (1), p.619-619, Article 619

2020

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

EMBO molecular medicine, 2019-12, Vol.11 (12), p.e11170-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

JAMA neurology, 2020-08, Vol.77 (8), p.955

2020

Link zum Volltext

Verfügbarkeit prüfen

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

Brain (London, England : 1878), 2017-09, Vol.140 (9), p.2286-2294

2017

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders

Scientific reports, 2018-09, Vol.8 (1), p.13276-9, Article 13276

2018

Link zum Volltext

Verfügbarkeit prüfen

Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition

Scientific reports, 2021-01, Vol.11 (1), p.1965-1965, Article 1965

2021

Link zum Volltext

Verfügbarkeit prüfen

Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum

PloS one, 2012-10, Vol.7 (10), p.e47387-e47387

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.073

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.039)
Mit Volltextzugriff
(955)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)

Menü

Weitere Dienste

Einstellungen

Biomarkers for neurodegenerative diseases

Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

Blood‐based biomarkers for Alzheimer's disease

Relationship between cortical iron and tau aggregation in Alzheimer's disease

CSF biomarkers and clinical progression of Parkinson disease

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders

Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition

Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum

Suchergebnisse filtern